Published in AIDS Weekly, December 21st, 1998
Recommended highly active antiretroviral therapy (HAART) regimens have always been based on the use of at least one protease inhibitor. But a head-to-head clinical trial showed that one member of a different class of anti-HIV drugs can be as potent - for 36 weeks at least.
The new drug, the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz, attracted intense interest when these results were announced at the 1998 World AIDS Conference. The findings paved the way for so-called "protease-sparing" HAART...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.